Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378591 | 0.86 | CNR2 (0.59) | CNR2CYP2C9CYP1A2CYP3A4 | |
| SCHEMBL5077117 | 0.83 | CNR2 (0.82) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3380666 | 0.83 | CNR2 (0.88) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4896457 | 0.83 | CNR2 (0.61) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL5778827 | 0.83 | CNR2 (0.74) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3378860 | 0.82 | CNR2 (0.62) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3380966 | 0.82 | CNR2 (0.85) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3378716 | 0.82 | CNR2 (0.85) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4884954 | 0.81 | CNR2 (0.55) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3381166 | 0.81 | CNR2 (0.84) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1718620-A1 | PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080350-A1 | PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | CNR2, CNR1, P2RY2 | CNR2 1/4885CYP2C9 729/4885CYP1A2 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.